How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about daratumumab

Marketing authorisation indication

2.1 Daratumumab (Darzalex, Janssen‑Cilag) in combination with bortezomib, thalidomide and dexamethasone, is indicated 'for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price for daratumumab is £4,320 per 1,800 mg vial of solution for injection intended for a fixed-dose subcutaneous administration (excluding VAT; BNF online, accessed May 2021). It is also available as a concentrate for solution for intravenous infusion with a list price of £360 per 100 mg vial, and £1,440 per 400 mg vial (excluding VAT; BNF online, accessed May 2021). The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount, which would have applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

2.4 The list price for bortezomib is £762.38 per 3.5 mg vial (excluding VAT; BNF online, accessed May 2021). There is a price reduction for bortezomib agreed with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.

2.5 The list price for thalidomide is £298.48 per 28-pack of 50-mg capsules (excluding VAT; BNF online, accessed May 2021).

2.6 There is a nationally available price reduction for dexamethasone with the Commercial Medicines Unit. The prices agreed through the framework are commercial in confidence.